America’s New Monkeypox Strategy Rests on a Single Study

Posted on AllSides August 10th, 2022
From The Left
Getty; Joanne Imperio/The Atlantic
OPINION

Once again, the United States is messing up its approach to vaccines. Three months into its monkeypox outbreak, just 620,000 doses of the two-injection Jynneos shot—the nation’s current best immune defense against the virus—have been shipped to states, not nearly enough to immunize the 1.6 million to 1.7 million Americans that the CDC considers at highest risk. The next deliveries from the manufacturer aren’t slated until September at the earliest. For now, we’re stuck with the stocks we’ve got.

Which is why the feds have turned to Inoculation Plan B: splitting Jynneos doses into...

Read full story
Some content from this outlet may be limited or behind a paywall.

The Atlantic

AllSides Media Bias Rating: Lean Left
AllSides Media Bias Rating: Lean Left
108336/84989
See full bias rating for The Atlantic
Learn about media bias
https://www.theatlantic.com/health/archive/2022/08/monkeypox-vaccine-splitting-doses-fda-gamble/671100/

More News about Public Health from the Left, Center and Right

From the Left

From the Center

From the Right